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Abstract
Background: Biopharmaceutical drugs are mainly recombinant proteins produced by biotechnological tools. The
patents of many biopharmaceuticals have expired, and biosimilars are thus currently being developed. Human granulocyte
colony stimulating factor (hG-CSF) is a hematopoietic cytokine that acts on cells of the neutrophil lineage causing
proliferation and differentiation of committed precursor cells and activation of mature neutrophils. Recombinant hG-CSF
has been produced in genetically engineered Escherichia coli (Filgrastim) and successfully used to treat cancer patients
suffering from chemotherapy-induced neutropenia. Filgrastim is a 175 amino acid protein, containing an extra N-terminal
methionine, which is needed for expression in E. coli. Here we describe a simple and low-cost process that is amenable
to scaling-up for the production and purification of homogeneous and active recombinant hG-CSF expressed in E. coli
cells.
Results: Here we describe cloning of the human granulocyte colony-stimulating factor coding DNA sequence, protein
expression in E. coli BL21(DE3) host cells in the absence of isopropyl-β-D-thiogalactopyranoside (IPTG) induction,
efficient isolation and solubilization of inclusion bodies by a multi-step washing procedure, and a purification protocol
using a single cationic exchange column. Characterization of homogeneous rhG-CSF by size exclusion and reverse phase
chromatography showed similar yields to the standard. The immunoassay and N-terminal sequencing confirmed the
identity of rhG-CSF. The biological activity assay, in vivo, showed an equivalent biological effect (109.4%) to the standard
reference rhG-CSF. The homogeneous rhG-CSF protein yield was 3.2 mg of bioactive protein per liter of cell culture.
Conclusion: The recombinant protein expression in the absence of IPTG induction is advantageous since cost is
reduced, and the protein purification protocol using a single chromatographic step should reduce cost even further for
large scale production. The physicochemical, immunological and biological analyses showed that this protocol can be
useful to develop therapeutic bioproducts. In summary, the combination of different experimental strategies presented
here allowed an efficient and cost-effective protocol for rhG-CSF production. These data may be of interest to
biopharmaceutical companies interested in developing biosimilars and healthcare community.
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Background
Biopharmaceuticals are medicinal products comprising
biotechnology-derived recombinant proteins as active
substances, according to the European Agency for the
Evaluation of Medicinal Products [1]. Biopharmaceuticals
have revolutionized the treatment of many diseases. Some
of the biopharmaceutical patents have already expired,
thereby allowing production of follow-on or biosimilar
products. Public and private sectors of a number of coun-
tries have been encouraged to share staff, funding and
facilities to increase technology transfers between univer-
sities and the industry [2]. It is due to an emerging multi-
billion-dollar market for companies willing to produce
biosimilar versions of these products and to potential sav-
ings for healthcare payers and consumers that represents a
driver of demand for biosimilars. Filgrastim (recombinant
human granulocyte colony stimulating factor, rhG-CSF),
produced by Amgen, had its patent expired in 2006. This
biopharmaceutical generated global sales of $5.6 billion
(June 2005 to June 2006) and its market in Europe and
USA has the potential to generate sales of approximately
$605 million in 2010 [3].
The granulocyte colony stimulating factor (G-CSF) is cen-
tral to neutrophil-based immune defenses due to its regu-
latory role in the growth, differentiation, survival, and
activation of neutrophils and their precursors [4]. Cancer
chemotherapy can suppress production of these white
blood cells, leaving patients vulnerable to potentially life-
threatening infections and sepsis. G-CSF has thus been
widely used with success in cancer patients whose treat-
ment requires high-dose chemotherapy [5]. Furthermore,
G-CSF can be used to reinforce the immune system in
patients with HIV, pneumonia, diabetic foot infections,
leukemia and febrile neutropenia [6-10]. Based on this
ample clinical application, the recombinant human G-
CSF has been produced in genetically engineered
Escherichia coli and was approved for use in chemother-
apy-induced neutropenia by the U.S Food and Drug
Administration in 1991 [11]. It should be pointed out
that two types of G-CSF are clinically available: a glyco-
sylated form (lenograstim) which is produced by using
the expression in mammalian cells, and nonglycosylated
form (filgrastim) which is produced by using the expres-
sion in E. coli.
Molecular cloning and expression of cDNA for hG-CSF
have been described [12,13]. The mature human G-CSF is
a 18.8 kDa protein of 174 amino-acid polypeptide chain
with two intra-molecular disulphide bonds between resi-
dues Cys36-Cys42 and Cys64-Cys74 and one free cysteine at
residue 17 [14]. Native hG-CSF has a single O-glycosyla-
tion site at Thr133, which protects the protein from aggre-
gation but is not crucial for biological activity [15]. The
recombinant hG-CSF produced by E.coli, has identical
biological activity to that of endogenous protein, but dif-
fers in that it contains an N-terminal methionine residue
and is not glycosylated.
Recent publications describe various protocols of cloning,
expression and purification of the rhG-CSF. These proto-
cols involve use of several chromatography columns, high
amount of detergents for the purification of G-CSF [16-
18] and some of them were not applicable to recombinant
G-CSF expressed in E. coli as inclusion bodies [19]. In
industry, production of biopharmaceuticals employing a
simple and cost-efffective process involving fewer steps
and yielding high levels of active protein is an essential
prerequisite.
Here we describe the cloning of recombinant human
granulocyte colony-stimulating factor gene, protein
expression in E. coli cells, a straightforward purification
protocol of the active recombinant protein from inclusion
bodies and characterization of rhG-CSF by analytical
methods. We believe that the combination of the different
experimental strategies presented here provides an effi-
cient protocol that may be useful in the industrial process
of rhG-CSF protein production.
Results and discussion
Sequence synthesis, cloning and expression
Synthesis of G-CSF coding DNA sequence was carried out
by a method developed in our laboratory, to which a pat-
ent has been filed [20]. We used the native sequence of
hG-CSF, without making any modification such as
replacement of GC rich regions with AT rich regions or
replacement of rare codons, as have been reported by oth-
ers [16,21,22]. A PCR amplification fragment consistent
with that expected for hG-CSF (522 bp) was detected on
agarose gel (Fig. 1), and its DNA sequence confirmed by
automatic sequencing. Recombinant hG-CSF protein was
expressed in insoluble form in E. coli BL21(DE3) host
cells. The best conditions for expression of the rhG-CSF
protein in the BL21(DE3) strain were reached at 24 hours
in the absence of IPTG induction. In the pET system, target
genes are positioned downstream of bacteriophage T7 late
promoter. Typically, production hosts contain a prophage
(λDE3) encoding the highly processive T7 RNA polymer-
ase under control of the IPTG-inducible lacUV5 promoter
that would ensure tight control of recombinant gene basal
expression [23]. In agreement with the results presented
here, high levels of protein expression in the absence of
inducer have been shown to occur in the pET system. It
has been proposed that protein expression in the absence
of induction is a property of lac-controlled system when
cells approach stationary phase in complex medium and
that cyclic AMP, acetate, and low pH are required to
achieve high-level expression in the absence of IPTG
induction, which may be part of a general cellularMicrobial Cell Factories 2008, 7:13 http://www.microbialcellfactories.com/content/7/1/13
Page 3 of 12
(page number not for citation purposes)
response to nutrition limitation [24]. We have previously
described this particular feature of the pET system for a
number of recombinant proteins [25-27]. The growth
rates were the same for Escherichia coli BL21(DE3) host
cells harboring either pET 23a(+) (control) or the recom-
binant pET 23a(+)::rhG-CSF plasmid. The absence of
IPTG induction to obtain protein expression is thus
advantageous since cost is reduced. The presence of the
rhG-CSF protein was not observed in the soluble fraction
of BL21(DE3) host cells (data not shown). SDS-PAGE
showed expression of an insoluble protein with a molec-
ular mass value consistent with that expected for rhG-CSF
(18.8 kDa) (Fig. 2). Interestingly, IPTG induction appears
to abolish expression of rhG-CSF (Fig. 2, lanes: 4, 8, 10,
14). As pointed out above, T7 RNA polymerase in the pET
system is under control of the IPTG-inducible lacUV5 pro-
moter, a system that has been used to produce substantial
amounts of target protein from a wide variety of genes.
However, a few proteins are made in disappointingly
small amounts, for reasons that are obvious in some cases
and obscure in others. Some likely reasons for obtaining
low levels of expression are as follows (pET System Man-
ual, Invitrogen): The target protein itself may interfere
with gene expression or with the integrity of the cell,
sometimes pulse labeling shows a gradual or rapid
decrease in the rate of protein synthesis as target protein
accumulates, or sometimes all protein synthesis stops
before any target protein can be detected, and occasion-
ally, considerable lysis of a culture is observed. More
recently, it has been shown that the predominant contrib-
utory factor for decreased production of target proteins
from pET plasmids is chromosomal mutation in the
prophage of BL21(λDE3) host cells, resulting in decreased
levels of functional T7 RNA Polymerase and ensuing
reduction in target protein expression [28]. However, the
reason for the lack of rhG-CSF protein expression
described here is not known yet.
Purification and characterization of the recombinant G-
CSF
The appropriate genetics for soluble protein production
has not yet been established and thus prevention of inclu-
sion body formation is essentially a trial-and-error proc-
ess. Aggregation may be minimized by controlling process
parameters such as temperature, reduction of recom-
binant protein expression rate, adjusting the codon usage,
or by co-expression of plasmid-encoded chaperones [29].
However, these strategies do not necessarily result in the
same degree of success for different polypeptide chains.
Notwithstanding, inclusion bodies can be easily purified
and these protein aggregates have also been observed as a
source of relatively pure polypeptide [29]. The recovery of
biologically active protein from inclusion bodies has sev-
eral advantages: large amounts of highly enriched protein
can be expressed as inclusion bodies; these aggregates are
resistant to proteolysis by E. coli proteases, allowing high-
yield protein production; facilitate production of protein
that can be toxic or lethal to the host cell, because inclu-
sion bodies have no biological activity; and, finally, it can
be isolated and purified, decreasing the downstream proc-
ess [30,31]. We have thus employed a strategy to recover
active protein from inclusion bodies as described by oth-
ers [32]. This strategy involves three steps: inclusion body
isolation and washing; solubilization of the aggregated
protein, and refolding of the solubilized protein. Non-
ionic detergents such as Triton × were used to solubilize
the bacterial cell wall components that contaminate the
inclusion body preparation. EDTA was added to chelate
divalent metal ions, which maintain the structural integ-
rity of the cell membrane. A second wash procedure incor-
porated sodium deoxycholate to remove any residual cell
debris particles, especially lipopolysaccharides units that
Agarose gel electrophoresis of PCR product Figure 1
Agarose gel electrophoresis of PCR product. Agarose 
gel (2%) electrophoresis of PCR amplified hG-CSF coding 
DNA sequence. Lane 1: DNA markers (1 Kb Plus DNA Lad-
der™, Life Technologies, Gibco BRL); lane 2: PCR amplifica-
tion of hG-CSF (522 bp).
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contribute to the unacceptable levels of endotoxins in
protein preparations from E. coli. The third step using
sodium chloride helps displace nucleic acids or any other
contaminants that are non-specifically bound to the G-
CSF protein in the inclusion bodies by ionic interactions.
rhG-CSF was further purified from inclusion bodies by a
cationic exchange column, yielding approximately 3.2 mg
of recombinant protein per liter of cell culture. Analysis by
SDS-PAGE from the final step of the purification showed
a single band of 18.8 kDa, similar to reference standard
(Fig. 3). The same general pattern was revealed when the
sample shown in Figure 3 was transferred from SDS-PAGE
to a nitrocellulose membrane and immunodetected with
G-CSF-specific antiserum, confirming a typical profile
(Fig. 4) as described by others [33,34]. The first 19 amino-
terminal amino acid residues of purified recombinant
protein were determined to be MTPLGPASSLPQSFLLKCL
by Edman degradation. These results unambiguously
demonstrate purification of rhG-CSF protein and that the
N-terminal methionine was not removed by post-transla-
tional processing.
The solubilization of inclusion bodies pellet method
described here employed a combination of small quantity
of denaturing agent (2 M urea) and high alkaline pH, dif-
ferent from the majority of the published protocols that
used high concentration of solubilizing agent (6 – 8 M).
Key to the development of an efficient and economic
denaturant-based solubilization step is the determination
of the minimum amount of denaturant needed to solubi-
lize the protein and to allow for full bioactivity recovery in
the refolding step. In addition, the purification protocol
of hG-CSF utilizes only one cation exchange column,
which is an improvement upon previous protocols that
utilized multiple chromatographic steps [16-18,35]. A
method has been described for G-CSF extraction from
inclusion bodies produced in E. coli that used high
amount of detergent and chaotropic agent, and hence
additional steps had to be employed to remove these
agents, including G-25, CM-cellulose and G-75 chromato-
graphic columns to obtain pure protein [16]. A G-CSF
purification protocol has been described that employed
immobilized metal affinity chromatography (IMAC)
matrix, cation exchange and gel filtration chromato-
Analysis of recombinant hG-CSF protein expression by SDS-PAGE Figure 2
Analysis of recombinant hG-CSF protein expression by SDS-PAGE. SDS-PAGE (12%) analysis showing the insoluble 
fractions of heterologous protein expression in E. coli BL21 (DE3) host cells transformed with either pET 23a(+) (control) or 
pET 23a(+)::hG-CSF. The best expression conditions were 24 h at 37°C without IPTG addition. Lane 1: Molecular mass mark-
ers (BenchMark™ Protein Ladder, Invitrogen), lanes 2,6,12: control induced with 0.4 mM IPTG and further growth for 3, 8 and 
24 h respectively; lanes 3,7,13: control without induction and further growth for 3, 8 and 24 h respectively; lanes 4,8,10,14: 
host cells containing the recombinant pET 23a(+)::hG-CSF plasmid induced with 0.4 mM IPTG and further growth for 3, 8, 17 
and 24 h respectively; and lanes 5,9,11,15: host cells containing the recombinant pET 23a(+)::hG-CSF plasmid without IPTG 
induction andd further growth for 3, 8,17 and 24 h respectively. The predicted molecular mass of rhG-CSF is 18.8 kDa.
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graphic steps, the final yields of the protein are not clearly
evident [18]. On a commercial scale, reducing the number
of protein purification steps is practical and economical
because each purification step not only adds to the cost of
the final product but also causes successive yield losses of
the recombinant protein.
Physicochemical properties
Characterization of a biological product (which includes
the determination of physicochemical properties, biolog-
ical activity, immunochemical properties, purity and
impurities) by appropriate techniques is necessary to con-
firm an efficient expression and purification protocols.
Protein instability encompasses many complicated and
interrelated physical and chemical processes. Any of these
can occur during the production, isolation and purifica-
tion of proteins. Chemical degradations that include, at
least, deamidation of Asparagine and Glutamine side
chain and oxidation of Methionine, as well as dimeric
forms and related substances of higher molecular mass,
have been recognized to be an important cause of partial
loss in activity of therapeutic proteins [36,37]. According
to Massiero and coworkers [38], rhG-CSF that undergoes
some form of degradation retains only 15% of biological
activity. The rhG-CSF here described was analysed by
HPLC to detect any of these alterations, including chemi-
cal degradation, dimers and related substances of higher
molecular mass.
SDS-PAGE of homogeneous rhG-CSF Figure 3
SDS-PAGE of homogeneous rhG-CSF. SDS-PAGE 
(12%) analysis of purified rhG-CSF showing a single protein 
band. Lane 1: Protein molecular mass markers (BenchMark™ 
Protein Ladder, Invitrogen), lane 2: homogeneous rhG-CSF 
(18.8 kDa) after elution from a cation exchange column, lane 
3: reference standard. Lanes 2 and 3 contain 1.5 μg of total 
protein each.
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Western blot of homogeneous rhG-CSF Figure 4
Western blot of homogeneous rhG-CSF. A single band 
was observed for rhG-CSF transferred to a nitrocellulose 
membrane and detected using a polyclonal antiserum. Lane 1: 
crude extract of host cells transformed with pET 23a(+)::hG-
CSF; lane 2: crude extract of host cells transformed with pET 
23a(+) (control); lane 3: insoluble fractions of host cells 
transformed with pET 23a(+)::hG-CSF; lane 4: insoluble frac-
tions of pET 23a(+); lane 5: homogeneous hG-CSF; lane 6: 
reference standard; and lane 7: protein molecular mass mark-
ers (Cruz Marker™).Microbial Cell Factories 2008, 7:13 http://www.microbialcellfactories.com/content/7/1/13
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Figure 5 shows a typical reverse-phase chromatogram of
rhG-CSF demonstrating the resolution of the symmetrical
peak that corresponds to hG-CSF with the retention time
of 31.6 min similar to standard. The deamidates and sul-
phoxides were analyzed (Fig. 5) and estimated to be
2.09% and 2.20%, respectively. These values are lower
than what is routinely regarded as safe level of 5% for
many biopharmaceuticals [39]. Acidic size-exclusion
chromatography of rhG-CSF (Fig. 6) demonstrates the
presence of a small amount of high molecular weight
aggregates (0.26%) and absence of dimers. This level is
lower than what is routinely regarded as safe (0.5%) for
many biopharmaceuticals [39]. The main peak represents
monomers eluted at a retention time similar to that of the
standard. Glycosylated G-CSF is freely soluble in phos-
phate-buffered saline. The absence of carbohydrate how-
ever results in a more hydrophobic protein that does not
tolerate high salt concentration or neutral pH. It is thus
necessary to run size-exclusion chromatography under
acidic conditions. At higher pH, recovery of monomers is
poor and multimers are irreversibly bound to the resin
[40]. The analytical results of recombinant hG-CSF pro-
tein reported here are similar to the reference standard.
The characterization of rhG-CSF plays a vital role in its
development as useful therapeutic agent. Physicochemi-
cal techniques can produce information about the struc-
ture and composition of this therapeutic protein, but
cannot yet predict their biological activity, for which bio-
logical assays are required.
Reverse-phase HPLC analysis of hG-CSF Figure 5
Reverse-phase HPLC analysis of hG-CSF. Sulphoxides and deamidates in hG-CSF were analyzed by Reverse-phase HPLC. 
200 μg mL-1 of either sample or standard was loaded for analysis. (A): homogeneous hG-CSF, peak 1-main peak. (B): reference 
standard, peak 1-main peak. Absorbance is in milliabsorbance units (mAU).
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Biological potency evaluation
In order to determine the biological potency of rhG-CSF
in the present study, we employed an in vivo model of
neutropenia, by treating mice with a single dose of ifos-
famine. The percentage of neutrophils in serum was mon-
itored 6 h after the last rhG-CSF injection or vehicle
injection. The data (Fig. 7) clearly demonstrate that treat-
ment with rh-GCSF in the sample group produced a sig-
nificant and dose-dependent increase of neutrophil
counts (P <0.001), when compared to the control group
(P < 0.001). The neutrophil counts in the standard group
were not significantly different from that observed in the
sample group when comparing the same doses of rhG-
CSF (P > 0.05, for the three doses).
Statistical analysis by the Finney test [41] revealed a bio-
logical activity of 109.4% for the rhG-CSF in the sample
group. It appears to be worth pointing out that the
potency of Filgrastim (rhG-CSF) itself is not described in
any Pharmacopoeia, although values ranging from 90 to
110% have been suggested for biological medicines,
according to the guidelines from the European Pharmaco-
poeia [42]. The data presented clearly indicate that the
rhG-CSF produced by the combination of experimental
strategies described here can produce biological effects
Size exclusion HPLC analysis of hG-CSF Figure 6
Size exclusion HPLC analysis of hG-CSF. Size-exclusion HPLC chromatography was employed to detect dimeric forms of 
hG-CSF. 200 μg mL-1 of either sample or standard was loaded for analysis. (A): homogeneous hG-CSF, peak 1-monomer and 
peak 2-excipient. (B): reference standard, peak 1-monomer and peak 2-excipient. Absorbance is in milliabsorbance units 
(mAU).
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that are comparable or even superior to those obtained
with the standard reference rhG-CSF. It is thus tempting to
infer that generation of rhG-CSF on a large scale using the
protocols described here may represent an interesting
option for producing biosimilars.
Conclusion
In this report, we describe an efficient protocol for clon-
ing, expression and purification of rhG-CSF. The recom-
binant protein expression in the absence of IPTG may be
advantageous since cost is reduced. In addition, the pro-
tein purification protocol by liquid chromatography
using a single chromatographic step may be a valuable
and cost-effective approach to large scale production. The
physicochemical, immunological and biological analyses
showed that this protocol can be useful to develop thera-
peutic bioproducts. The data presented here may be of
interest to biopharmaceutical companies interested in
developing biosimilars, which offer a great opportunity to
scientific, economical and industrial growth.
Methods
Amplification, cloning and overexpression of hG-CSF 
coding DNA sequence
Oligonucleotides were manually designed and synthe-
sized, in even numbers, corresponding to the double
stranded DNA, in a sequential manner. The G-CSF nucle-
otide sequence (Accession number NM_000759) of 522
bp, was divided in 12 short sequences of approximately
50 bp each. Oligonucleotides contained overlapping
regions of about 10 bases at their 5'- and 3'-ends. The pairs
of oligonucleotides were assembled and PCR amplified to
yield the hG-CSF coding DNA sequence in a step-wise
fashion. PCR-amplified DNA fragments with the expected
sizes were detected by 2% agarose gel electrophoresis
stained with 0.5 μg mL-1 of Ethidium Bromide, purified
Biological assay for hG-CSF Figure 7
Biological assay for hG-CSF. Serum neutrophil counts after treatment with rhG-CSF. Mice in the standard and the sample 
groups were treated with different doses of rhG-CSF (4, 12, and 36 μg/0.5 ml/mouse). The control group was treated with 
vehicle (0.1% BSA in PBS). The asterisks represent significant differences in comparison to the control group (** P<0.001). N = 
6 mice per group.
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and another round of PCR amplification carried out. A
thorough description of this method has been presented
elsewhere [20]. The primers employed in the present
study are given in Table 1. The primers P1 and P12 con-
tained the restriction sites for, respectively, Nde I and Bam
HI. The 522 bp final PCR product was agarose-gel purified
and cloned into the pCR®-Blunt vector (Invitrogen) and
subcloned into the pET 23a(+) expression vector (Nova-
gen) using the Nde I and Bam HI restriction enzymes (Boe-
hringer Mannheim). The nucleotide sequence of rhG-CSF
was determined in order to confirm the identity, integrity,
and absence of PCR-introduced mutations in the cloned
gene. Escherichia coli BL21(DE3) (Novagen) electrocom-
petent cells were transformed with the recombinant pET
23a(+)::rhG-CSF plasmid and grown on LB agar plates
containing 50 μg mL-1 of ampicillin. The protocol for
recombinant protein expression described here represents
a choice from a number of tests carried out at different
experimental conditions. Soluble and insoluble fractions
were analyzed by 12% SDS-PAGE [43]. To express and
purify the recombinant protein, two liters of 4YT medium
(32 g Bacto tryptone, 20 g yeast extract and 5 g NaCl per
litre, pH 7.2) containing ampicillin were inoculated with
a single colony and grown in shaker flasks for 24 h at 180
rpm and 37°C without IPTG induction. Cells were har-
vested by centrifugation at 15,900 × g for 30 min at 4°C
and stored at -20°C.
Isolation of inclusion bodies
The frozen cell paste was resuspended in lysis buffer (50
mM Tris buffer, at pH 8.0, 1 mM EDTA and 1 mM PMSF)
at a pellet:buffer ratio of 1:10 (w/v). The inclusion bodies
containing rhG-CSF were recovered from the cells using a
French press (Constant Systems LTD) under 137.9 MPa.
Prior to centrifugation, a 1:2 dilution of the lysate was car-
ried out to reduce viscosity and to obtain a better yield of
inclusion bodies. The resulting lysate solution was centri-
fuged at 48,000 × g for 30 minutes at 4°C to pellet the
inclusion bodies. The supernatant was discarded, and the
fraction containing the inclusion bodies was subjected to
a three-step wash procedure to eliminate endotoxins, pro-
teins and DNA of the host cells. In all steps, the pellet was
suspended in the specific buffer at 1:40 (w/v) ratio at
room temperature, stirred for 30 min and re-pellet by cen-
trifugation. The first buffer was comprised of: 50 mM Tris,
pH 8.0, 5 mM EDTA and 2% Triton ×-100. The composi-
tion of the second buffer was 50 mM Tris, pH 8.0, 5 mM
EDTA, 1% sodium deoxycholate. In the third wash step,
the wash buffer contained 50 mM Tris buffer, pH 8.0, 5
mM EDTA, and 1 M NaCl.
Solubilization and purification
The protocol of solubilization and denaturation of rhG-
CSF in inclusion bodies employed a combination of solu-
bilization agent (2 M urea) and high alkaline pH. The sol-
ubilized pellet was stirred for 30 min at room
temperature, after diluting the protein to a concentration
of 2 mg mL-1. Acetic acid was added to bring the pH to a
value of 8.0. Refolding of 190 mL of the solubilized pro-
tein was carried out by dialysis (MWCO 6,000–8,000 Da)
in two steps for 12–16 hours. The first one was carried out
against 4 L 50 mM Tris HCl pH 8.0 and the second step
against 4 L 25 mM sodium acetate buffer pH 4.5 (buffer
A). The purification protocol was performed using the
ÄKTA System (GE Healthcare). The soluble protein was
purified on a cation exchange column, HiPrep Resource S
column (GE Healthcare), preequilibrated with buffer A,
and the adsorbed material was washed with buffer A (4
column volumes), eluted with a linear gradient of 0.2 to
0.26 M Tris HCl pH 8.0 (10 column volumes), 0.26 – 1.0
M Tris HCl pH 8.0 (5 column volumes), followed by an
isocratic elution with 1.0 M Tris HCl pH 8.0 (5 column
volumes) at a flow rate of 1 mL min-1. The recombinant
hG-CSF eluted between 0.207 – 0.215 M Tris HCl pH 8.0.
Protein expression and all protein purification steps were
analyzed by 12% SDS-PAGE, and protein concentrations
were determined by the method of Bradford et al. [44]
(Bio-Rad Laboratories).
Table 1: Oligonucleotides employed to obtain the coding DNA sequence of hG-CSF*.
P1-5' AA CATATGACCCCCCTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTC AAGTG 3'
P2-5' GCGCTGCGCCATCGCCCTGGATCTTCCTCACTTGCTCTAAGCACTTGAGCA 3'
P3-5' GGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCT 3'
P4-5' CCAGAGAGTGTCCGAGCAGCACCAGCTCCTCGGGGTGGCACAGCTTGTAGG 3'
P5-5' CACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCAGCTGCCCCAGCCAGGCCCTG CAG 3'
P6-5' GGTAGAGGAAAAGGCCGCTATGGAGTTGGCTCAAGCAGCCTGCCAGCTGCA GGGCC 3'
P7-5' TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATCTCCCCCGAGTTGGGT C 3'
P8-5' TGGTGGCAAAGTCGGCGACGTCCAGCTGCAGTGTGTCCAAGGTGGGACCCAACT C 3'
P9'-5' TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCC CT 3'
P10-5' AAAGCAGAGGCGAAGGCCGGCATGGCACCCTGGGTGGGCTGCAGGGCAGGGG 3'
P11-5' CCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCCTCCCATCTGC AGAGCTTCC 3'
P12-5'AA GGATCCTCAGGGCTGGGCAAGGTGGCGTAGAACGCGGTACGACACCTCCAGGAAGCTCTG 3'
* Primer sequences for construction of hG-CSF. The G-CSF nucleotide sequence (Accession number NM_000759) of 522 bp, was divided into 12 
DNA sequences of approximately 50 bp each, containing 10-bp overlapping regions at their 5'- and 3'-ends for adjacent oligonucleotides. The 
restriction sites, Nde I and Bam HI, are underlined in primers P1 and P12, respectively.Microbial Cell Factories 2008, 7:13 http://www.microbialcellfactories.com/content/7/1/13
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N-terminal amino acid sequencing
The N-terminal amino acid residues of homogeneous
recombinant hG-CSF were identified by automated
Edman degradation sequencing as we have described else-
where [45].
Western Blotting
Recombinant rhG-CSF on 12% SDS-PAGE was transferred
to a nitrocellulose membrane by electrophoresis at a con-
stant voltage of 70 V in 25 mM Tris pH 8.8, 192 mM gly-
cine, containing methanol 20%, for 1 h using a Trans-blot
apparatus (Bio-Rad, USA). The membrane was blocked
for 1 h at room temperature by 50 mM sodium phos-
phate, 150 mM sodium chloride pH 7.0, containing 5%
(w/v) dried skim milk powder. The membrane was incu-
bated for 1 h at room temperature with 1.5 μg G-CSF pol-
yclonal antibody (Santa Cruz Biotechnology), in milk-
containing phosphate buffered saline as above. The blot
was then incubated with a secondary antibody conjugated
with horseradish peroxidase (HRPO) (1:1000), and
diaminobenzidine (DAB) was used for the development
of signal. The size (molecular mass) of the protein was
compared to pre-loaded standards (Santa Cruz ™ molecu-
lar weight standards).
Reverse phase liquid chromatography (RP-HPLC) analysis
The sulphoxides and deamidates were analyzed as we
have described elsewhere [46]. A HPLC system (Shi-
madzu, Kyoto, Japan) equipped with an SCL-10Avp sys-
tem controller, LC-10ADvp  pump, DGU-14A degasser,
SIL-10ADvp autosampler, and an SPD-M10Avp photodi-
ode array (PDA) detector was used. The detector was set at
280 nm and peak areas were integrated automatically by
computational analysis, using a Shimadzu Class VP® soft-
ware program. The experiments were carried out on
reversed phase Phenomenex (Torrance, USA) Jupiter C4
column (250 × 4.6 mm I.D, with a pore size of 30 nm).
The liquid chromatography system was operated at con-
trolled room temperature (25°C). The elution was per-
formed by a fast gradient at a constant flow rate of 0.5 mL
min-1. Mobile phase A consisted of water: acetonitrile
(90:10 v/v) containing 0.1% trifluoroacetic acid (TFA)
and mobile phase B consisted of water: acetonitrile
(20:80, v/v) containing 0.1% TFA. The injection volume
was 50 μL for both standard and sample. The Filgrastim
substance reference used was from NIBISC (National
Institute for Biological Standards and Control).
Size exclusion chromatography (SEC-HPLC) analysis
The detection of dimers and monomers was performed as
we have described elsewhere [33]. The HPLC system (Shi-
madzu, Kyoto, Japan) equipped with an SCL-10Avp sys-
tem controller, LC-10ADvp  pump, DGU-14A degasser,
SIL-10ADvp autosampler, and an SPD-M10Avp photodi-
ode array (PDA) detector was used. The detector was set at
214 nm and peak areas were integrated automatically by
computational analysis, using a Shimadzu Class VP® soft-
ware program. The experiments were carried out on size
exclusion Phenomenex (Torrance, USA) BioSep-SEC 2000
column (300 × 7.8 mm I.D., with a particle size of 5 μm
and pore size of 14.5 nm). The HPLC system was operated
at room temperature, using mobile phase of phosphoric
acid (pH 2.5; 0.1 M) adjusted by the addition of sodium
hydroxide (10 N). At the beginning of the run, 50 μL
bovine albumin (1 mg mL-1) was injected to reduce non-
specific adsorption. The injection volume was the same
for both, standards and samples, and all determinations
were carried out in triplicate. Flow rate was maintained at
1 mL min-1. The Filgrastim substance reference used was
from NIBISC (National Institute for Biological Standards
and Control).
Biological Assay
Male 7–8 week-old BALB-c mice (19 – 24 g) obtained
from the Department of Industrial Pharmacy, Health Sci-
ence Centre, Universidade Federal de Santa Maria (Brazil),
were used in this study. Animals were housed under con-
ditions of optimum light, temperature and humidity (12
h light-dark cycle, 22 ± 2°C, 65% humidity), with food
and water provided ad libitum. All procedures used in the
present study were approved by "Principles of Laboratory
Animal Care" from NIH publication No. 85-23 and were
approved by the local Animal Ethics Committee with the
registration number 19/2005. The number of animals
used was the minimum necessary to demonstrate the con-
sistent effects.
The animals were allocated to sample, standard, and con-
trol groups in a fully randomized order and identified by
color code for assay (6 mice per group). Standard and test
sample were diluted to the concentrations of 4, 12, and 36
μg mL-1, in phosphate buffered saline (PBS), containing
0.1% bovine serum albumin (BSA). To induce neutrope-
nia, all mice received a single dose of ifosfamine (4.3 mg/
0.5 mL per animal) by intraperitoneal route, on day 0,
according to the methodology we have described else-
where [46]. Animals in the treated groups received multi-
ple injections of 0.5 mL rhG-CSF (standard or sample
groups), from day 1 to day 4. The control group was
treated with vehicle (0.1% BSA in PBS) at the same sched-
ule of administration. Six hours after the last rhG-CSF
injection or vehicle, peripheral blood was collected from
the orbital venus sinus. Smears were prepared on glass
slides and stained by the May-Grünwald-Giemsa method,
and the white cells were counted and expressed as the
total number of neutrophils. The Filgrastim standard used
was from NIBISC (National Institute for Biological Stand-
ards and Control).Microbial Cell Factories 2008, 7:13 http://www.microbialcellfactories.com/content/7/1/13
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Statistical analysis
The results (% of neutrophils) are presented as the mean
± S.D. of 6 animals. Statistical comparison of data was per-
formed by one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni's post-test, by means of GraphPad
Prism Program (Version 4.0). P-values less than 0.05 (P <
0.05 or less) were considered significant.
For determining the possible differences in the biological
activity between the standard and the sample groups, the
test described by Finney [41] was adopted, through the
parallel line method (3 × 3), using a PLA 1.2 program
(Stegmann Systemberatung, Rodgau, Germany). Analysis
of variance was performed for each assay, and the assump-
tion of linearity and parallelism of the log dose-log
response lines was tested (P < 0.05). Statistical weights
were computed as the reciprocal of the variance of the log
potency. Estimates of log potency were examined for het-
erogeneity using a χ2 test (P = 0.05) and were combined as
weight geometric means of homogeneous estimates (P >
0.05) [47].
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